Clinical trials: Functional Gastrointestinal Disorders
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
Depressive Symptoms
EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision)…
- Trial name
- SAMEUP (NCT03932474)
- Testing
- SAMEUp
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Nutrilinea srl
Irritable Bowel Syndrome
Irritable Bowel Syndrome and Lactibiane Tolerance
The purpose of this study is to evaluate the effects of a probiotic combination (Lactibiane Tolerance) on the severity of symptoms in patients with irritable bowel syndrome (IBS).
- Trial name
- NCT01529359
- Testing
- Lactibiane Tolerance
- Where
- France
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- PiLeJe
Irritable Bowel Syndrome, Vaginal Health
A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health
This is a virtual single-group study that will last 12 weeks. Participants will take 1 capsule every day, with water. Questionnaires will be completed at baseline, 2 weeks, 4 weeks, and 12 weeks.
- Trial name
- NCT06124313
- Testing
- Vaginal Probiotic
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rael
Irritable Bowel Syndrome (IBS)
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
This is a double-blind, placebo-controlled, randomised crossover study to investigate the efficacy and safety of GW876008
- Trial name
- NCT00421707
- Testing
- GW876008
- Where
- 23 sites in United States, Canada
- Volunteers
- 133 people
- Sponsor
- GlaxoSmithKline
Non-alcoholic Steatohepatitis (NASH)
A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
Novo Nordisk is developing the study medicine NNC0194-0499 for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver.
- Trial name
- NCT05727644
- Testing
- NNC0194-0499
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Irritable Bowel Syndrome, Gallstone Disease
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in…
- Conditions
- Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia
- Trial name
- NCT07421011
- Testing
- Trimedat®
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Hepatitis C
Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease
The purpose of the study is to determine how Asunaprevir is handled by the body of subjects with kidney disease compared with subjects with normal kidney function
- Trial name
- NCT01886599
- Testing
- Asunaprevir
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
This randomized study evaluates the effectiveness of the a probiotic formula, compared with the antibiotic rifaximin, in the treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome (IBS) patients.
- Trial name
- NCT04316806
- Testing
- Probiotic, Rifaximin
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- AB Biotics, SA
IBS - Irritable Bowel Syndrome, Depression, Anxiety
The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome
This study aimed to assess the impact of consumption of COMBO, a combination product of two Bifidobacterium longum strains, on stress, mood and bowel symptoms in adults with Irritable Bowel Syndrome (IBS).
- Trial name
- IBS (NCT04422327)
- Testing
- Probiotic capsule
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- PrecisionBiotics Group Ltd.
Hepatic Insufficiency
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics
- Trial name
- NCT06390410
- Testing
- Simufilam
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Cassava Sciences, Inc.
IBS - Irritable Bowel Syndrome
Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)
The aim of the study is to demonstrate a beneficial effect in reducing symptoms that negatively affect the quality of life of IBS patients, and to demonstrate a positive effect on inflammatory and intestinal function markers.
- Trial name
- NCT05990764
- Testing
- Probiotic, Prebiotic, Polyphenol-rich Extracts, Probiotic, Prebiotic
- Where
- Poland
- Volunteers
- 48 people
- Sponsor
- AronPharma Sp. z o. o.
Liver Diseases, Hepatic Impairment
A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
The purpose of this study is to learn how the study medicine (PF-07923568) is processed in participants with liver function loss compared to healthy participants.
- Trial name
- NCT05857644
- Testing
- PF-07923568
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cystic Fibrosis
Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis
The purpose of this study is to confirm the improvement in pulmonary function and cytokine levels observed in the recently completed multidose aerosol study for the treatment of Cystic Fibrosis (CF).
- Trial name
- NCT00073463
- Testing
- tgAAVCF
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Targeted Genetics Corporation
Ileus, Gastro-Intestinal Disorder
A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.
- Trial name
- INTEGRITY (NCT05470387)
- Testing
- LB1148
- Where
- 23 sites in United States
- Volunteers
- 23 people
- Sponsor
- Palisade Bio
Irritable Bowel Syndrome
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.
- Trial name
- NCT06206265
- Testing
- TRYP-0082, Psychotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- TRYP Therapeutics
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation
This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. The difference of responder rate between test group (10, 20 and 40mg) and placebo will be evaluated.
- Trial name
- YKP (NCT02082457)
- Testing
- YKP10811 5mg, YKP10811 20mg
- Where
- South Korea
- Volunteers
- 273 people
- Sponsor
- SK Chemicals Co., Ltd.
Short Bowel Syndrome, Malabsorption Syndromes
Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
A 24-week, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and tolerability of crofelemer in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC)…
- Conditions
- Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome, Post-Op Complication
- Trial name
- CRO-SBS-IF (NCT06904872)
- Testing
- Crofelemer Powder for Oral Solution
- Where
- 8 sites in Germany, Italy
- Volunteers
- 18 people
- Sponsor
- Napo Therapeutics, S.p.A.
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome